Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial.
Tang J, Xu Q, Zhu C, Xuan K, Li T, Li Q, Pang X, Zha Z, Li J, Qiao L, Xu H, Wu G, Tian Y, Han J, Gao C, Yi J, Qian G, Tian X, Xie L.
Tang J, et al. Among authors: pang x.
Vaccines (Basel). 2024 Feb 8;12(2):175. doi: 10.3390/vaccines12020175.
Vaccines (Basel). 2024.
PMID: 38400158
Free PMC article.